Alcoholic steatohepatitis: Management and prognosis

Current Gastroenterology Reports

Volumn 9, Issue 1, 2007, Pages 39-46

  Maher, Jacquelyn J ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; BILIRUBIN; CORTICOSTEROID; DEFEROXAMINE; ETANERCEPT; INFLIXIMAB; MEDIUM CHAIN TRIACYLGLYCEROL; METHIONINE; METHYLPREDNISOLONE; PENTOXIFYLLINE; PLACEBO; PREDNISOLONE; S ADENOSYLMETHIONINE; SELENIUM;

ALCOHOL LIVER DISEASE; BILIRUBIN BLOOD LEVEL; CASE MANAGEMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC APPROACH ROUTE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; ENTERIC FEEDING; HIGH RISK PATIENT; HUMAN; MEDICAL CARE; MORTALITY; NAUSEA AND VOMITING; NUTRITIONAL SUPPORT; PATIENT IDENTIFICATION; PROGNOSIS; REVIEW; SCORING SYSTEM; STEATITIS; TUBE FEEDING;

ADRENAL CORTEX HORMONES; FATTY LIVER, ALCOHOLIC; HEPATITIS, ALCOHOLIC; HUMANS; NUTRITIONAL SUPPORT; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33947672905     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-008-0019-6     Document Type: Review

References (43)

1. Mathurin P, Duchatelle V, Ramond MJ, et al.: Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996, 110:1847-1853.
2. Ramond MJ, Poynard T, Rueff B, et al.: A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992, 326:507-512.
3. Thabut D, Naveau S, Charlotte F, et al.: The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. J Hepatol 2006, 44:1175-1185.
4. Goldberg S, Mendenhall C, Anderson S, et al.: VA Cooperative Study on Alcoholic Hepatitis. IV. The significance of clinically mild alcoholic hepatitis - describing the population with minimal hyperbilirubinemia. Am J Gastroenterol 1986, 81:1029-1034.
5. Maddrey WC, Boitnott JK, Bedine MS, et al.: Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978, 75:193-199.
6. Carithers RL Jr, Herlong HF, Diehl AM, et al.: Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial [see comments]. Ann Intern Med 1989, 110:685-690.
7. Akriviadis E, Botla R, Briggs W, et al.: Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:1637-1648.
8. Forrest EH, Evans CD, Stewart S, et al.: Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow Alcoholic Hepatitis Score. Gut 2005, 54:1174-1179.
9. Dunn W, Jamil LH, Brown LS, et al.: MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005, 41:353-358.
10. Kulkarni K, Tran T, Medrano M, et al.: The role of the discriminant factor in the assessment and treatment of alcoholic hepatitis. J Clin Gastroenterol 2004, 38:453-459.
11. Sheth M, Riggs M, Patel T.- Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002, 2:2.
12. Srikureja W, Kyulo NL, Runyon BA, Hu KQ: MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol 2005, 42:700-706.
13. Mendenhall CL, Anderson S, Garcia-Pont P, et al.: Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 1984, 311:1464-1470.
14. Mathurin P, Mendenhall CL, Carithers RL, Jr., et al.: Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002, 36:480-487.
15. Christensen E, Gluud C: Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables [see comments]. Gut 1995, 37:113-118.
16. Imperiale TF, McCullough AJ: Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 1990, 113:299-307.
17. McCullough AJ, O'Connor JF: Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol 1998, 93:2022-2036.
18. Chariton M: Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl 2003, 9:S58-S62.
19. Magy N, Cribier B, Schmitt C, et al.: Effects of corticosteroids on HCV infection. Int J Immunopharmacol 1999, 21:253-261.
20. McClain C, Barve S, Joshi-Barve S, et al.: Dysregulated cytokine metabolism, altered hepatic methionine metabolism and proteasome dysfunction in alcoholic liver disease. Alcohol Clin Exp Res 2005, 29:180S-188S.
21. Ehrly AM: Drugs that alter blood viscosity. Their role in therapy. Drugs 1990, 39:155-159.
22. Mendenhall C, Roselle GA, Gartside P, Moritz T: Relationship of protein calorie malnutrition to alcoholic liver disease: a reexammation of data from two Veterans AdnAmstration Cooperative Studies. Alcohol Clin Exp Res 1995, 19:635-641.
23. Plauth M, Cabre E, Riggio O, et al.: ESPEN Guidelines on enteral nutrition: Liver disease. Clin Nutr 2006, 25:285-294.
24. Alvarez MA, Cabre E, Lorenzo-Zuniga V, et al.: Combining steroids with enteral nutrition: a better therapeutic strategy for severe alcoholic hepatitis? Results of a pilot study. Eur J Gastroenterol Hepatol 2004, 16:1375-1380.
25. Cabre E, Rodriguez-Iglesias P, Caballeria J, et al.: Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000, 32:36-42.
26. Kono H, Enomoto N, Connor HD, et al.: Medium-chain triglycerides inhibit free radical formation and TNF-alpha production in rats given enteral ethanol. Am J Physiol 2000, 278:G467-G476.
27. Nanji AA, Yang EK, Fogt F, et al.: Medium chain triglycerides and vitamin E reduce the severity of established experimental alcoholic liver disease. J Pharmacol Exp Ther 1996, 277:1694-1700.
28. Menon KV, Stadheim L, Kamath PS, et al.: A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004, 99:255-260.
29. Spahr L, Rubbia-Brandt L, Frossard JL, et al.: Combination of steroids with infliximalb or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002, 37:448-455.
30. Tilg H, Jalan R, Kaser A, et al.: Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003, 38:419-425.
31. Naveau S, Chollet-Martin S, Dharancy S, et al.: A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004, 39:1390-1397.
32. Mathurin P: Corticosteroids for alcoholic hepatitis - what's next? J Hepatol 2005, 43:526-533.
33. Phillips M, Curtis H, Portmann B, et al.: Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis - a randomised clinical trial. J Hepatol 2006, 44:784-790.
34. Mezey E, Potter JJ, Rennie-Tankersley L, et al.: A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. J Hepatol 2004, 40:40-46.
35. Jalan R, Sen S, Steiner C, et al.: Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol 2003, 38:24-31.
36. Laleman W, Wilmer A, Evenepoel P, et al.: Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006, 10:R108.
37. Sen S, Mookerjee RP, Cheshire LM, et al.: Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J Hepatol 2005, 43:142-148.
38. Verma S, Ajudia K, Mendler M, Redeker A: Prevalence of septic events, type 1 hepatorenal syndrome, and mortality in severe alcoholic hepatitis and utility of discriminant function and MELD score in predicting these adverse events. Dig Dis Sci 2006, 51:1637-1643.
39. Chedid A, Mendenhall CL, Gartside P, et al.: Prognostic factors in alcoholic liver disease. VA Cooperative Study Group. Am J Gastroenterol 1991, 86:210-216.
40. Orrego H, Blake JE, Blendis LM, Medline A: Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis. Gastroenterology 1987, 92:208-214.
41. Mathurin P, Abdelnour M, Ramond MJ, et al.: Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 2003, 38:1363-1369.
42. Morris JM, Forrest EH: Bilirubin response to corticosteroids in severe alcoholic hepatitis. Eur J Gastroenterol Hepatol 2005, 17:759-762.
43. Mato JM, Camara J, Fernandez de Paz J, et al.: S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999, 30:1081-1089.